Next Article in Journal
Four Novel PAX9 Variants and the PAX9-Related Non-Syndromic Tooth Agenesis Patterns
Next Article in Special Issue
SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma
Previous Article in Journal
Photocatalytic Degradation of Some Typical Antibiotics: Recent Advances and Future Outlooks
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 15
10.3390/ijms23158141
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

Int. J. Mol. Sci. 2022, 23(15), 8141; https://doi.org/10.3390/ijms23158141
by Rahma K. Alseksek 1,2, Wafaa S. Ramadan 2,*, Ekram Saleh 3 and Raafat El-Awady 1,2,*
Reviewer 1:
Jonathan R. Dimmock
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(15), 8141; https://doi.org/10.3390/ijms23158141
Submission received: 7 July 2022 / Revised: 14 July 2022 / Accepted: 15 July 2022 / Published: 24 July 2022
(This article belongs to the Special Issue Anticancer Drugs Activity and Underlying Mechanism)

Round 1

Reviewer 1 Report

This review covers a great deal of territory regarding an important cluster of bioactive agents.

In general the text flows well and is clear but there is certainly room for improvement as the following comments reveal.

1.  The wording of the bottom line of the Abstract is indistinct. Similarly at the bottom of Figure 1.

2.  There are inappropriate choice of words on occasions such as "wretched' (line 69), "outrageous" (157), inconsistent (158, 167), sighted (169), add 'up" to give "to sum up" (436), "the" to be inserted before tumor (484), "of" to be removed (501, 709), spelling of mitochondria is spelled incorrectly (Figure 5), above mentioned (581), "grant" should be replaced by "allow" (651) and lines 691 / line 692 needs rephrasing.

Apart from these considerations, this review is recommended for publication.

 

 

Author Response

We thank the reviewer for his/her valuable comments. All suggested modifications/revisions have been introduced into the revised version of the manuscript

Reviewer 2 Report

The manuscript is well structured and contains a good overview of the field of HDAC inhibitors and their molecular mechanisms especially regarding cellular stress. In some places the authors could add more recent references and important results. Especially in paragraph 4 where immunotherapies are described. Here an entry on the interaction of the PDL1 system with different HDAC subtypes would be appropriate. 

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Zhou Y, Jin X, Yu H, Qin G, Pan P, Zhao J, Chen T, Liang X, Sun Y, Wang B, Ren D, Zhu S, Wu H. Theranostics. 2022 Jan 31;12(5):2080-2094.

 

HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Li X, Su X, Liu R, Pan Y, Fang J, Cao L, Feng C, Shang Q, Chen Y, Shao C, Shi Y. Oncogene. 2021 Mar;40(10):1836-1850.

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, Tang W, Tu Y, Xu L, Wu F, Tan Z, Sun H, Tian Y, Wong J, Lai PB, Chan SL, Chan AW, Tan PB, Chen Z, Sung JJ, Yip KY, To KF, Cheng AS. Sci Transl Med. 2021 Apr 7;13(588):eaaz6804.

Author Response

Thank you very much for the valuable revision

References have been modified as suggested and the three recommended references have been added to the article

Back to TopTop